Molecular and biological aspects of forecasting the oncological efficiency of cytoreductive surgery in metastatic colon cancer

Abstract

Through an immunohistochemical study, the molecular biological properties of adenocarcinoma in patients with stage IV colorectal cancer with synchronous unresectable liver metastases, who underwent cytoreductive interventions for volume removal of the primary tumor, were examined. This study clarified the criteria for selecting patients with stage IV colon cancer with unresectable synchronous metastases in the liver for cytoreductive surgery from the standpoint of the molecular biological properties of the tumor. The prognostic significance of immunohistochemical markers such as the index of proliferative activity of stem cancer cells (ALDH + Ki-67 +) and the receptor for chemokines CXCR4 was established. The level of their expression correlates with the life expectancy of patients who underwent cytoreductive surgery. Thus, the high proliferative activity of cancer stem cells (ALDH + Ki67 + > 50%) and the high expression of chemokine receptor (CXCR4 > 70%) correlate with the rapid disease progression after surgical treatment. A significant inverse relationship was traced between the expression level of the receptor for chemokine CXCR4 as well as the proliferative activity of cancer stem cells and life expectancy of patients with stage IV colon cancer after cytoreductive surgery. The expediency of immunohistochemical studies in patients with metastatic colon cancer has been substantiated. Its implementation provides important information about the potential for tumor aggressiveness, which makes it possible to clarify the indications for performing cytoreductive surgery and improve the results of surgical treatment of this category of patients.

Keywords

metastatic colon cancer / immunohistochemical study / synchronous metastases of colorectal cancer in the liver / primary tumor / cytoreductive surgery / prognostic factors

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI: 10.3322/caac.21492

[2] Bray F., Ferlay J., Soerjomataram I., et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2018. Vol. 68, No. 6. P. 394–424. DOI: 10.3322/caac.21492

[3] Kaprin AD, Starinskij AD, Petrova GV. Sostoyanie onkologicheskoj pomoshchi naseleniyu Rossii v 2017 godu. Moscow: MNIOI PA. Gercena filial FGBU «NMIRC» Minzdrava Rossii; 2018. 236 p. (In Russ.).

[4] Каприн А.Д., Старинский А.Д., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П.А. Герцена — филиал ФГБУ «НМИРЦ» Минздрава России, 2018. 236 с.

[5] Afanas’ev SG, Dobrodeev AYU. Citoreduktivnye operacii (Nuzhno li udalyat’ pervichnuyu opuhol’? Gde predel razumnoj citoredukcii?). Practical Oncology. 2014;15(2):93–100. (In Russ.).

[6] Афанасьев С.Г., Добродеев А.Ю. Циторедуктивные операции (Нужно ли удалять первичную опухоль? Где предел разумной циторедукции?) // Практическая онкология. 2014. Т. 15, № 2. С. 93–100.

[7] Hrykov GN, Strukov EYu, Romashchenko PN, et al. Rannyaya reabilitaciya posle hirurgicheskogo lecheniya raka obodochnoj kishki u bol’nyh pozhilogo i starcheskogo vozrasta. Bulletin of the Russian Military Medical Academy. 2014;(2):400. (In Russ.).

[8] Хрыков Г.Н., Струков Е.Ю., Ромащенко П.Н., и др. Ранняя реабилитация после хирургического лечения рака ободочной кишки у больных пожилого и старческого возраста // Вестник Российской военно-медицинской академии. 2014. № 2. С.400.

[9] Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg. 2010;34(4): 797–807. DOI: 10.1007/s00268-009-0366-y

[10] Stillwell A.P., Buettner P.G., Ho Y.H. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone // World J Surg. 2010. Vol. 34, No. 4. P. 797–807. DOI: 10.1007/s00268-009-0366-y

[11] Aslam MI, Kelkar A, Sharpe D, Jameson JS. Ten years experience of managing the primary tumors in patients with stage IV colorectal cancers. Int J Surg. 2010;8(4):305–313. DOI: 10.1016/j.ijsu.2010.03.005

[12] Aslam M.I., Kelkar A., Sharpe D., Jameson J.S. Ten years experience of managing the primary tumors in patients with stage IV colorectal cancers // Int J Surg. 2010. Vol. 8, No. 4. P. 305–313. DOI: 10.1016/j.ijsu.2010.03.005

[13] Ferrand F, Malka D, Bourredjem A. Impact of primary tumor resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy. Eur J Cancer. 2013;49(1):90–97. DOI: 10.1016/j.ejca.2012.07.006

[14] Ferrand F., Malka D., Bourredjem A. Impact of primary tumor resection on survival of patients with colorectal cancer and synchronous metastases treated by chemotherapy // Eur J Cancer. 2013. Vol. 49, No. 1. P. 90–97. DOI: 10.1016/j.ejca.2012.07.006

[15] Wang X, Mao M, Xu G. The incidence, associated factors and predictive nomogram for early death in stage IV colorectal cancer. International Journal of Colorectal Disease. 2019;34(7):1189–1201. DOI: 10.1007/s00384-019-03306-1

[16] Wang X., Mao M., Xu G. The incidence, associated factors and predictive nomogram for early death in stage IV colorectal cancer // International Journal of Colorectal Disease. 2019. Vol. 34, No. 7. P. 1189–1201. DOI: 10.1007/s00384-019-03306-1

[17] Raskin GA. Kliniko-morfologicheskaya ocenka prognosticheskih i prediktivnyh faktorov pri adenokarcinome tolstoj kishki: Dis. … d-ra. med. nauk. Saint Petersburg; 2015. 238 p. (In Russ.). Available from: https://search.rsl.ru/ru/record/01005557331

[18] Раскин Г.А. Клинико-морфологическая оценка прогностических и предиктивных факторов при аденокарциноме толстой кишки: дис. … д-ра мед. наук. СПб., 2015. 238 с. Режим доступа: https://search.rsl.ru/ru/record/01005557331. Дата обращения: 08.07.21.

[19] Manihas GM, Majstrenko NA, Sazonov AA. influence of the age factor and tumor immunophenotype on the effectiveness of cytoreductive operations in metastatic colorectal cancer. Problems in Oncology. 2019;65(6):855–862. (In Russ.).

[20] Манихас Г.М., Майстренко Н.А., Сазонов А.А. Влияние возрастного фактора и иммунофенотипа опухоли на эффективность циторедуктивных операций при метастатическом раке толстой кишки // Вопросы онкологии. 2019. Т. 65, № 6. С. 855–862.

[21] Perfil’eva YV, Abdolla NN, Kustova EA. Ekspressiya markerov adgezii CD62L, CD44 i CXCR4 na NK-kletkah pri onkologicheskih zabolevaniyah. Cytokines and Inflammation. 2012;11(1):86–90. (In Russ.).

[22] Перфильева Ю.В., Абдолла Н.Н., Кустова Е.А. Экспрессия маркеров адгезии CD62L, CD44 и CXCR4 на NK-клетках при онкологических заболеваниях // Цитокины и воспаление. 2012. Т. 11, № 1. С. 86–90.

[23] Xu X, Pan Y, Feng Z. Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts. Br J of Cancer. 2019;120(10):987–995. DOI: 10.1038/s41416-019-0450-5

[24] Xu X., Pan Y., Feng Z. Low tumour PPM1H indicates poor prognosis in colorectal cancer via activation of cancer-associated fibroblasts // Br J of Cancer. 2019;120(10):987–995. DOI: 10.1038/s41416-019-0450-5

RIGHTS & PERMISSIONS

Sazonov A.A., Maistrenko N.A., Romashchenko P.N.